GlassScriptPhysician profile
Ginna L Granroth
NPI 1477980092
$211,478.39
in general payments reported to CMS, 2019-2025
27 companies · $65K in 2025
The $65K reported for 2025 was more than what 99% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $8,594 · 2022: $50K · 2023: $32K · 2024: $55K · 2025: $65K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $92K · Travel and Lodging: $30K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $12K · Food and Beverage: $11K · Consulting Fee: $6,753 · Education: $156.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $92,230.50 |
| Travel and Lodging | $30,311.17 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $12,387.65 |
| Food and Beverage | $11,058.98 |
| Consulting Fee | $6,752.50 |
| Education | $155.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $68,684.93 | 2021-2025 | Jakafi, Jakafi, Niktimvo |
| Sobi, INC | $48,283.76 | 2024-2025 | |
| Cti Biopharma Corp. | $48,091.16 | 2022-2023 | Vonjo |
| Kite Pharma, INC. | $18,230.00 | 2023-2025 | Yescarta |
| E.R. Squibb & Sons, L.L.C. | $17,184.81 | 2023-2025 | Breyanzi, Abecma, Reblozyl |
| Abbvie INC. | $3,777.81 | 2023-2025 | |
| Genmab U.S., INC. | $3,023.85 | 2025 | Epkinly |
| Glaxosmithkline, LLC. | $1,149.70 | 2022-2025 | Ojjaara |
| Celgene Corporation | $836.48 | 2022-2025 | Pomalyst, Breyanzi, Reblozyl |
| Janssen Biotech, INC. | $328.67 | 2023-2025 | Darzalex, Tecvayli, Talvey |
| Pfizer INC. | $248.63 | 2023-2025 | |
| Janssen Scientific Affairs, LLC | $229.50 | 2024-2025 | Talvey, Balversa |
| Lilly USA, LLC | $217.65 | 2021 | |
| Rigel Pharmaceuticals, INC. | $162.66 | 2023 | Rezlidhia, Tavalisse |
| Pharmacyclics LLC, An Abbvie Company | $162.54 | 2023 | Epkinly |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $157.15 | 2023 | |
| Fennec Pharmaceuticals, INC. | $146.09 | 2025 | Fyarro |
| Daiichi Sankyo INC. | $141.01 | 2024-2025 | Enhertu |
| Merck Sharp & Dohme LLC | $120.90 | 2023-2025 | Keytruda, Lynparza |
| Stemline Therapeutics INC. | $102.52 | 2024 | Elzonris |
| Seagen INC. | $57.95 | 2023 | Tukysa, Padcev |
| Regeneron Healthcare Solutions, INC. | $29.62 | 2025 | Lynozyfic |
| Genzyme Corporation | $27.75 | 2025 | |
| Springworks Therapeutics, INC. | $27.14 | 2024 | Ogsiveo |
| Legend Biotech USA INC. | $20.79 | 2024 | |
| Astellas Pharma US INC | $17.96 | 2023 | Xospata |
| Eisai INC. | $17.36 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ginna Granroth listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.